Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of amivantamab + carboplatin + pembrolizumab vs standard platinum + pembrolizumab + 5-FU in first-line recurrent/metastatic head and neck squamous cell carcinoma
2025-521917-24-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Amivantamab + carboplatin + pembrolizumab with Standard-of-care platinum + pembrolizumab + 5-FU (2 arms). Primary endpoint: Overall Survival. Planned start Jan 2026; status: authorised.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-521917-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521917-24-00.